BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017
Topical Minocycline Gel Offers Potential Advantages in the Treatment of Inflammatory Skin Diseases
Findings to be presented at antibacterial drug developers meeting in Boston
Oct 18, 2017
MENLO PARK, Calif., Oct. 18, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may be useful in the treatment of inflammatory skin diseases, including acne and papulopustular rosacea, particularly as the medical community has growing concerns about antibiotic resistance secondary to systemic exposure.
A presentation at the Re-entering Antibacterial Discovery and Development Summit on Oct. 18-20 in Boston concludes that minocycline is effective in fighting gram-positive and gram-negative bacteria, as well as other micro-organisms implicated in rosacea and acne – while also alleviating the inflammation they cause. Many antibiotic therapies used today fight bacteria in the skin, but do little to alleviate the inflammation or the associated discomfort.
The poster, entitled "Development of Minocycline (BPX-01) as a Topical Treatment for Acne Vulgaris and Rosacea," reports that pre-clinical study findings of no or low erythema suggest that topical administration of minocycline may be useful for the treatment of inflammatory skin diseases. It also reports that BPX-01 topical minocycline was well tolerated among clinical trial participants and that more than 85 percent of subjects said they would use it again.
BioPharmX is the first company to develop an effective topical formulation of minocycline thereby taking full advantage of its potential in treating inflammatory skin diseases while minimizing systemic exposure. BPX-01 is the first topical gel formulation of minocycline that can penetrate the skin to deliver the antibiotic to the pilosebaceous unit, where acne- and rosacea-associated inflammation develops. It is also the first and only stable hydrophilic and non-oil-based topical gel comprising of fully solubilized minocycline, rather than crystal suspension of the active ingredient.
"Research shows BPX-01 unleashes the potential therapeutic advantages of minocycline for the treatment of acne and rosacea by efficient delivery to the area of the skin where these diseases emerge," said Kin F. Chan, PHD, executive vice president of research and development at BioPharmX.
The company's clinical studies are designed to confirm whether BPX-01 can effectively treat acne and rosacea with lower, safer dosages of the antibiotic.
BPX-011 is a hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that has been shown to penetrate the skin to deliver the antibiotic to its target. Following positive results from its previously announced phase 2b study of BPX-01 in acne, BioPharmX continues with phase 3 clinical study plans for BPX-01 for the treatment of acne.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
1Caution: BPX-01 is a new drug limited by U.S. law to investigational use.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, email@example.com (650) 889-5030; OR Jim Martinez, firstname.lastname@example.org (312) 543-9026